375 related articles for article (PubMed ID: 26308073)
1. Cysteine cathepsin activity suppresses osteoclastogenesis of myeloid-derived suppressor cells in breast cancer.
Edgington-Mitchell LE; Rautela J; Duivenvoorden HM; Jayatilleke KM; van der Linden WA; Verdoes M; Bogyo M; Parker BS
Oncotarget; 2015 Sep; 6(29):27008-22. PubMed ID: 26308073
[TBL] [Abstract][Full Text] [Related]
2. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
Wilson TJ; Nannuru KC; Futakuchi M; Sadanandam A; Singh RK
Cancer Res; 2008 Jul; 68(14):5803-11. PubMed ID: 18632634
[TBL] [Abstract][Full Text] [Related]
3. Cysteine cathepsins L and X differentially modulate interactions between myeloid-derived suppressor cells and tumor cells.
Jakoš T; Pišlar A; Pečar Fonović U; Švajger U; Kos J
Cancer Immunol Immunother; 2020 Sep; 69(9):1869-1880. PubMed ID: 32372139
[TBL] [Abstract][Full Text] [Related]
4. CST6 protein and peptides inhibit breast cancer bone metastasis by suppressing CTSB activity and osteoclastogenesis.
Li X; Liang Y; Lian C; Peng F; Xiao Y; He Y; Ma C; Wang Y; Zhang P; Deng Y; Su Y; Luo C; Kong X; Yang Q; Liu T; Hu G
Theranostics; 2021; 11(20):9821-9832. PubMed ID: 34815788
[No Abstract] [Full Text] [Related]
5. Cathepsin G recruits osteoclast precursors via proteolytic activation of protease-activated receptor-1.
Wilson TJ; Nannuru KC; Singh RK
Cancer Res; 2009 Apr; 69(7):3188-95. PubMed ID: 19293192
[TBL] [Abstract][Full Text] [Related]
6. Different cysteine proteinases involved in bone resorption and osteoclast formation.
Brage M; Abrahamson M; Lindström V; Grubb A; Lerner UH
Calcif Tissue Int; 2005 Jun; 76(6):439-47. PubMed ID: 15906014
[TBL] [Abstract][Full Text] [Related]
7. Enhanced expression of cathepsin L in metastatic bone tumors.
Park IC; Lee SY; Jeon DG; Lee JS; Hwang CS; Hwang BG; Lee SH; Hong WS; Hong SI
J Korean Med Sci; 1996 Apr; 11(2):144-8. PubMed ID: 8835762
[TBL] [Abstract][Full Text] [Related]
8. Cathepsin K inhibitors as treatment of bone metastasis.
Le Gall C; Bonnelye E; Clézardin P
Curr Opin Support Palliat Care; 2008 Sep; 2(3):218-22. PubMed ID: 18685424
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis.
Marino S; Bishop RT; Mollat P; Idris AI
Calcif Tissue Int; 2018 Aug; 103(2):206-216. PubMed ID: 29455416
[TBL] [Abstract][Full Text] [Related]
10. Lysosomal protein turnover contributes to the acquisition of TGFβ-1 induced invasive properties of mammary cancer cells.
Kern U; Wischnewski V; Biniossek ML; Schilling O; Reinheckel T
Mol Cancer; 2015 Feb; 14():39. PubMed ID: 25744631
[TBL] [Abstract][Full Text] [Related]
11. Tumor cell- and microenvironment-specific roles of cysteine cathepsins in mouse models of human cancers.
Hölzen L; Parigiani MA; Reinheckel T
Biochim Biophys Acta Proteins Proteom; 2020 Jul; 1868(7):140423. PubMed ID: 32247787
[TBL] [Abstract][Full Text] [Related]
12. Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model.
Sudhan DR; Pampo C; Rice L; Siemann DW
Int J Cancer; 2016 Jun; 138(11):2665-77. PubMed ID: 26757413
[TBL] [Abstract][Full Text] [Related]
13. Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer.
Sawant A; Deshane J; Jules J; Lee CM; Harris BA; Feng X; Ponnazhagan S
Cancer Res; 2013 Jan; 73(2):672-82. PubMed ID: 23243021
[TBL] [Abstract][Full Text] [Related]
14. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
[TBL] [Abstract][Full Text] [Related]
15. Identification of a myeloid-derived suppressor cell cystatin-like protein that inhibits metastasis.
Boutté AM; Friedman DB; Bogyo M; Min Y; Yang L; Lin PC
FASEB J; 2011 Aug; 25(8):2626-37. PubMed ID: 21518852
[TBL] [Abstract][Full Text] [Related]
16. Cathepsin K mRNA detection is restricted to osteoclasts during fetal mouse development.
Dodds RA; Connor JR; Drake F; Feild J; Gowen M
J Bone Miner Res; 1998 Apr; 13(4):673-82. PubMed ID: 9556067
[TBL] [Abstract][Full Text] [Related]
17. Primary tumour expression of the cysteine cathepsin inhibitor Stefin A inhibits distant metastasis in breast cancer.
Parker BS; Ciocca DR; Bidwell BN; Gago FE; Fanelli MA; George J; Slavin JL; Möller A; Steel R; Pouliot N; Eckhardt B; Henderson MA; Anderson RL
J Pathol; 2008 Feb; 214(3):337-46. PubMed ID: 17985332
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of osteoclast differentiation and bone resorption by cathepsin K antisense oligonucleotides.
Ishikawa T; Kamiyama M; Tani-Ishii N; Suzuki H; Ichikawa Y; Hamaguchi Y; Momiyama N; Shimada H
Mol Carcinog; 2001 Oct; 32(2):84-91. PubMed ID: 11746820
[TBL] [Abstract][Full Text] [Related]
19. Calvarial osteoclasts express a higher level of tartrate-resistant acid phosphatase than long bone osteoclasts and activation does not depend on cathepsin K or L activity.
Perez-Amodio S; Jansen DC; Schoenmaker T; Vogels IM; Reinheckel T; Hayman AR; Cox TM; Saftig P; Beertsen W; Everts V
Calcif Tissue Int; 2006 Oct; 79(4):245-54. PubMed ID: 17033726
[TBL] [Abstract][Full Text] [Related]
20. Cysteine-type cathepsins promote the effector phase of acute cutaneous delayed-type hypersensitivity reactions.
Schwenck J; Maurer A; Fehrenbacher B; Mehling R; Knopf P; Mucha N; Haupt D; Fuchs K; Griessinger CM; Bukala D; Holstein J; Schaller M; Menendez IG; Ghoreschi K; Quintanilla-Martinez L; Gütschow M; Laufer S; Reinheckel T; Röcken M; Kalbacher H; Pichler BJ; Kneilling M
Theranostics; 2019; 9(13):3903-3917. PubMed ID: 31281521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
